These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 21187474)
1. Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours. Królicka A; Kobierzycki C; Puła B; Podhorska-Okołów M; Piotrowska A; Rzeszutko M; Rzeszutko W; Rabczyński J; Domosławski P; Wojtczak B; Dawiskiba J; Dzięgiel P Anticancer Res; 2010 Dec; 30(12):4945-9. PubMed ID: 21187474 [TBL] [Abstract][Full Text] [Related]
2. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687 [TBL] [Abstract][Full Text] [Related]
3. Role of metallothionein expression in non-small cell lung carcinomas. Dziegiel P; Jeleń M; Muszczyńska B; Maciejczyk A; Szulc A; Podhorska-Okołów M; Cegielski M; Zabel M Rocz Akad Med Bialymst; 2004; 49 Suppl 1():43-5. PubMed ID: 15638370 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Pastuszewski W; Dziegiel P; Krecicki T; Podhorska-Okolow M; Ciesielska U; Gorzynska E; Zabel M Anticancer Res; 2007; 27(1A):335-42. PubMed ID: 17352251 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501 [TBL] [Abstract][Full Text] [Related]
8. Analysis of P161NK4A protein expression in follicular thyroid tumors. Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201 [TBL] [Abstract][Full Text] [Related]
9. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Cho Mar K; Eimoto T; Nagaya S; Tateyama H Histopathology; 2006 Jun; 48(7):801-7. PubMed ID: 16722928 [TBL] [Abstract][Full Text] [Related]
10. Role of Ki-67 as a proliferative marker in lesions of thyroid. Pujani M; Arora B; Pujani M; Singh SK; Tejwani N Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907 [TBL] [Abstract][Full Text] [Related]
11. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Werynska B; Pula B; Muszczynska-Bernhard B; Piotrowska A; Jethon A; Podhorska-Okolow M; Dziegiel P; Jankowska R Anticancer Res; 2011 Sep; 31(9):2833-9. PubMed ID: 21868526 [TBL] [Abstract][Full Text] [Related]
12. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Yasuoka H; Kakudo K; Inohara H; Kuma K; Miyauchi A Pathology; 2005 Aug; 37(4):296-8. PubMed ID: 16194828 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712 [TBL] [Abstract][Full Text] [Related]
14. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors. Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419 [TBL] [Abstract][Full Text] [Related]
17. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607 [TBL] [Abstract][Full Text] [Related]
18. Galectin-3 is a presurgical marker of human thyroid carcinoma. Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965 [TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies. Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546 [TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors. West J; Munoz-Antonia T; Johnson JG; Klotch D; Muro-Cacho CA Laryngoscope; 2000 Aug; 110(8):1323-7. PubMed ID: 10942134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]